Loading...
Loading...
EYPT| Name | Value |
|---|---|
| Revenues | 11.7M |
| Cost of Revenue | 0.8M |
| Gross Profit | 10.9M |
| Operating Expense | 44.2M |
| Operating I/L | -33.3M |
| Other Income/Expense | 4.0M |
| Interest Income | 4.0M |
| Pretax | -29.3M |
| Income Tax Expense | -0.0M |
| Net Income/Loss | -29.3M |
EyePoint Pharmaceuticals, Inc. develops and commercializes ophthalmic products for the treatment of eye diseases, including ILUVIEN for diabetic macular edema, YUTIQ for chronic non-infectious uveitis, and DEXYCU for post-operative ocular inflammation. The company is also developing EYP-1901, a bioerodible formulation for wet age-related macular degeneration and other conditions. EyePoint has strategic collaborations with Alimera Sciences, Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC, as well as a commercial alliance with ImprimisRx PA, Inc. for DEXYCU promotion.
